[A22-38] Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2022
Project no.:
A22-38
Commission:
Commission awarded on 01.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Children and adolescents aged 6 to < 18 years who are infected with HIV
Result of dossier assessment:
- Treatment-naive adolescents aged 12 to < 18 years who are infected with HIV: added benefit not proven
- Treatment-experienced adolescents aged 12 to < 18 years who are infected with HIV: added benefit not proven
- Treatment-naive children aged 6 to < 12 year who are infected with HIV-1: added benefit not proven
- Treatment-experienced children aged 6 to < 12 years who are infected with HIV-1: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-14 | Dolutegravir (HIV infection in children aged >= 4 weeks to < 6 years) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-11 | Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-08 | Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |